Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells

European Journal of Pharmacology

Volumn 602, Issue 1, 2009, Pages 124-131

  Wu, Liang ^a   Zhu, Lei ^a   Shi, Wei Hao ^a   Zhang, Jin ^b   Ma, Duan ^b   Yu, Bo ^a  

^a FUDAN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Atherosclerosis; Bisphosphonates; Intimal hyperplasia; Vascular smooth muscle cells; Zoledronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN; FOCAL ADHESION KINASE; PLATELET DERIVED GROWTH FACTOR BB; ZOLEDRONIC ACID;

ANIMAL CELL; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CELL ADHESION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; DRUG INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BONE DENSITY CONSERVATION AGENTS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; IMIDAZOLES; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 57249113715     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.10.043     Document Type: Article

References (48)

1. Andres V. Control of vascular smooth muscle cell growth and its implication in atherosclerosis and restenosis. Int J Mol Med 2 (1998) 81-89
2. Berenson J., Ravera C., Ma P., Deckert F., Sasaki Y., Saeki T., Takashima S., LoRusso P., Goodin S., Seaman J., Schran H., and Zhou H. Population pharmacokinetics (PK) of Zometa. Proc Am Soc Clin Oncol 19 (2000) 209a (Abstract 814)
3. Boissier S., Magnetto S., Frappart L., Cuzin B., Ebetino F.H., Delmas P.D., and Clezardin P. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57 (1997) 3890-3894
4. Caraglia M., D'Alessandro A.M., Marra M., Giuberti G., Vitale G., Viscomi C., Colao A., Del Prete S., Tagliaferri P., Tassone P., Budillon A., Venuta S., and Abbruzzese A. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. Oncogene 23 (2004) 6900-6913
5. Cohen-Sela E., Rosenzweig O., Gao J., Epstein H., Gati I., Reich R., Danenberg H.D., and Golomb G. Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis. J Control Release 113 (2006) 23-30
6. Danenberg H.D., Fishbein I., Gao J., Monkkonen J., Reich R., Gati I., Moerman E., and Golomb G. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation 106 (2002) 599-605
7. Danenberg H.D., Golomb G., Groothuis A., Gao J., Epstein H., Swaminathan R.V., Seifert P., and Edelman E.R. Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation 108 (2003) 2798-2804
8. Daoud A.S., Frank A.S., Jarmolych J., and Fritz K.E. The effect of ethane-1-hydroxy-11 diphosphonate (EHDP) on necrosis of atherosclerotic lesions. Atherosclerosis 67 (1987) 41-48
9. Davies M.G., and Hagen P.O. Pathobiology of intimal hyperplasia. Br J Surg 81 (1994) 1254-1269
10. Delafontaine P. Growth factors and vascular smooth muscle cell growth responses. Eur Heart J 19 (1998) G18-22
11. Epstein H., Berger V., Levi I., Eisenberg G., Koroukhov N., Gao J., and Golomb G. Nanosuspensions of alendronate with gallium or gadolinium attenuate neointimal hyperplasia in rats. J Control Release 117 (2007) 322-332
12. Evdokiou A., Labrinidis A., Bouralexis S., Hay S., Findlay D.M., Evdokiou A., Labrinidis A., Bouralexis S., Hay S., and Findlay D.M. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone 33 (2003) 216-228
13. Garrioch S., Ebetino F.H., and Rogers M.J. Bisphosphonates prevent adhesion of breast cancer cells to bone in vitro by inhibiting protein prenylation. J Bone Miner Res 20 (2005) 1294
14. Gerthoffer W.T., and Gunst S.J. Invited review: focal adhesion and small heat shock proteins in the regulation of actin remodeling and contractility in smooth muscle. J Appl Physiol 91 (2001) 963-972
15. Green J.R. Preclinical pharmacology of zoledronic acid. Semin Oncol 29 (2002) 3-11
16. Hanke H., Strohschneider T., Oberhoff M., Betz E., and Karsch K.R. Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. Circ Res 67 (1990) 651-659
17. Hasmim M., Bieler G., and Ruegg C. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost 5 (2007) 166-173
18. Hoch J.R., Stark V.K., Van Rooijen N., Kim J.L., Nutt M.P., and Warner T.F. Macrophage depletion alters vein graft intimal hyperplasia. Surgery 126 (1999) 428-437
19. Hou Y.Z., Yang J., Zhao G.R., and Yuan Y.J. Ferulic acid inhibits vascular smooth muscle cell proliferation induced by angiotensin II. Eur J Pharmacol 499 (2004) 85-90
20. Ibrahim A., Scher N., Williams G., Sridhara R., Li N., Chen G., Leighton J., Booth B., Gobburu J.V., Rahman A., Hsieh Y., Wood R., Vause D., and Pazdur R. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 9 (2003) 2394-2399
21. Jaiswal J.K., Andrews N.W., and Simon S.M. Membrane proximal lysosomes are the major vesicles responsible for calcium-dependent exocytosis in nonsecretory cells. J Cell Biol 159 (2002) 625-635
22. Kamiya K., Ryer E., Sakakibara K., Zohlman A., Kent K.C., and Liu B. Protein kinase C delta activated adhesion regulates vascular smooth muscle cell migration. J Surg Res 141 (2007) 91-96
23. Koshiyama H., Nakamura Y., Tanaka S., and Minamikawa J. Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes. J Clin Endocrinol Metab 85 (2000) 2793-2796
24. Koutsouki E., Beeching C.A., Slater S.C., Blaschuk O.W., Sala-Newby G.B., and George S.J. N-cadherin-dependent cell-cell contacts promote human saphenous vein smooth muscle cell survival. Arterioscler Thromb Vasc Biol 25 (2005) 982-988
25. Li Y.Y., Chang J.W., Chou W.C., Liaw C.C., Wang H.M., Huang J.S., Wang C.H., and Yeh K.Y. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer 59 (2008) 180-191
26. Lortholary A. Tumor-induced hypercalcemia. A review of the treatment by bisphosphonates. Rev Med Interne 22 (2001) 648-652
27. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., and Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13 (1998) 581-589
28. Merlotti D., Gennari L., Martini G., Valleggi F., De Paola V., Avanzati A., and Nuti R. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone. J Bone Miner Res 22 (2007) 1510-1517
29. Morla A.O., and Mogford J.E. Control of smooth muscle cell proliferation and phenotype by integrin signaling through focal adhesion kinase. Biochem Biophys Res Commun 272 (2000) 298-302
30. Mullins C., and Bonifacino J.S. The molecular machinery for lysosome biogenesis. Bioessays 23 (2001) 333-343
31. Ohtsuka Y., Manabe A., Kawasaki H., Hasegawa D., Zaike Y., Watanabe S., Tanizawa T., Nakahata T., and Tsuji K. RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro. Blood 106 (2005) 3134-3141
32. Owens G., Jackson R., and Lewiecki E.M. An integrated approach: Bisphosphonate management for the treatment of osteoporosis. Am J Manag Care. 13 (2007) S290-S308
33. Panetti T.S. Tyrosine phosphorylation of paxillin, FAK, and p130CAS: effects on cell spreading and migration. Front Biosci 7 (2002) d143-d150
34. Peest D., and Ganser A. Therapy of multiple myeloma: indications and options. Internist 48 (2007) 1343
35. Pietschmann P., Stohlawetz P., Brosch S., Steiner G., Smolen J.S., and Peterlik M. The effect of alendronate on cytokine production, adhesion molecule expression, and transendothelial migration of human peripheral blood mononuclear cells. Calcif Tissue Int 63 (1998) 325-330
36. Ross R. Cellular and molecular studies of atherogenesis. Atherosclerosis 131 (1997) S3-S4
37. Stevenson P.H., and Stevenson J.R. Cytotoxic and migration inhibitory effects of bisphosphonates on macrophages. Calcif Tissue Int 38 (1986) 227-233
38. Su J.Z., Fukuda N., Kishioka H., Hu W.Y., and Kanmatsuse K. Etidronate influences growth and phenotype of rat vascular smooth muscle cells. Pharmacol Res 46 (2002) 7-13
39. Tassone P., Tagliaferri P., Viscomi C., Palmieri C., Caraglia M., D'Alessandro A., Galea E., Goel A., Abbruzzese A., Boland C.R., and Venuta S. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 88 (2003) 1971-1978
40. Tenenbaum H.C., Torontali M., and Sukhu B. Effects of bisphosphonates and inorganic pyrophosphate on osteogenesis in vitro. Bone 13 (1992) 249-255
41. Van Beek E., Pieterman E., Cohen L., Lowik C., and Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res 264 (1999) 108-111
42. Webb D.J., Parsons J.T., and Horwitz A.F. Adhesion assembly, disassembly and turnover in migrating cells - over and over and over again. Nat Cell Biol 4 (2002) E97-E100
43. Webste P., Ortego J., and Andrews N.W. Lysosomes behave as Ca2+-regulated exocytic vesicles in fibroblasts and epithelial cells. J Cell Biol 137 (1997) 93-104
44. Ylitalo R., Oksala O., Ylaherttuala S., and Ylitalo P. Effects of clodronate (dichloromethylene bisphosphonate) on the development of experimental atherosclerosis in rabbits. J Lab Clin Med 123 (1994) 769-776
45. Ylitalo R., Monkkonen J., Urtti A., and Ylitalo P. Accumulation of bisphosphonates in the aorta and some other tissues of healthy and atherosclerotic rabbits. J Lab Clin Med 127 (1996) 200-206
46. Ylitalo R., Kalliovalkama J., Wu X.M., Kankaanranta H., Salenius J.P., Sisto T., Lahteenmaki T., Ylitalo P., and Porsti I. Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. Pharmacol Toxicol 83 (1998) 125-131
47. Zerial M., and McBride H. Rab proteins as membrane organizers. Nat Rev Mol Cell Biol 2 (2001) 107-117
48. Zhang F.L., and Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65 (1996) 241-269